Abstract: A power injector system having a power injector for enabling delivery of fluid in an injection procedure to be performed on a patient may include one or more processors; a first user interface; and a second user interface. The first user interface and the second user interface may be configured to accept a plurality of user inputs associated with control of a plurality of operations of the power injector system and display information associated with the plurality of operations. One of the first user interface and the second user interface may be proximate to the power injector and the other may be remote from the power injector. The one or more processors may be programmed and/or configured to independently control the first user interface and the second user interface based on a first user input and a next user input received from the first user interface and/or the second user interface.

Abstract: Provided is a method for determining whether a horse is normal, a carrier, or is affected with Lavender Foal Syndrome (LFS). The method entails, in a biological sample obtained or derived from a horse, determining a single nucleotide deletion which introduces a translational stop codon in the 49th codon of exon 30 of the equine MYO5A gene. Homozygosity for the absence of the deletion is indicative that the horse is normal for LFS. Heterozygosity for the deletion is indicative that the horse is a carrier of LFS. Homozygosity for the deletion is indicative that the horse is affected with LFS. Methods for selecting horses for breeding and kits for determining the LFS-associated deletion are also provided.

Abstract: A method for screening for a Tobiano genotype includes obtaining a nucleic acid from an equine animal, and analyzing the nucleic acid for the presence of an inversion in a chromosome ECA3q which is indicative of the genotype for Tobiano. The method includes detecting at least one of a telomeric breakpoint of an inverted ECA3q chromosome and/or a centromeric breakpoint of an inverted ECA3q chromosome. In one embodiment, the nucleic acid may be analyzed by the steps of hybridizing the group of probes or primers having the sequences set forth herein in SEQ ID NO:8, SEQ ID NO: 9, and SEQ ID NO: 10, or sequences complementary thereto, and preparing an amplification product. A 209 bp nucleic acid amplification product (SEQ ID NO:11) indicates the presence of the inversion.

Abstract: Provided is a method for determining whether a horse is normal, a carrier, or is affected with Lavender Foal Syndrome (LFS). The method entails, in a biological sample obtained or derived from a horse, determining a single nucleotide deletion which introduces a translational stop codon in the 49th codon of exon 30 of the equine MYO5A gene. Homozyogosity for the absence of the deletion is indicative that the horse is normal for LFS. Heterozygosity for the deletion is indicative that the horse is a carrier of LFS. Homozygosity for the deletion is indicative that the horse is affected with LFS. Methods for selecting horses for breeding and kits for determining the LFS-associated deletion are also provided.

Abstract: A method for screening for a Tobiano genotype includes obtaining a nucleic acid from an equine animal, and analyzing the nucleic acid for the presence of an inversion in a chromosome ECA3q which is indicative of the genotype for Tobiano. The method includes detecting at least one of a telomeric breakpoint of an inverted ECA3q chromosome and/or a centromeric breakpoint of an inverted ECA3q chromosome. In one embodiment, the nucleic acid may be analyzed by the steps of hybridizing the group of probes or primers having the sequences set forth herein in SEQ ID NO:8, SEQ ID NO: 9, and SEQ ID NO: 10, or sequences complementary thereto, and preparing an amplification product. A 209 bp nucleic acid amplification product (SEQ ID NO:11) indicates the presence of the inversion.